Conditions: Type 2 Diabetes (T2D)
Keywords: Type 2 diabetes (T2D)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: yes

Brief summary:
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.

Detailed description:

Arms:
arm 1: Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A). arm 2: Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A). arm 3: Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B). arm 4: Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).

Interventions: intervention 1: Omarigliptin intervention 2: Placebo
Intervention descriptions: intervention 1: Once-weekly 50 mg capsule intervention 2: Once-weekly placebo capsule

Protocol document: